Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies
- 1 July 2023
- journal article
- editorial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 43 (7) , 1093-1095
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse ModelsCirculation, 2023
- Bridging the Gap With Clinical Pharmacology in Innovative Rare Disease Treatment Modalities: Targeting DNA to RNA to ProteinThe Journal of Clinical Pharmacology, 2022
- An Overview of Genome Editing in Cardiovascular and Metabolic Diseases2022
- The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible ReformsJournal of Health Politics, Policy and Law, 2022
- Therapeutic application of genome editing in dyslipidemiaCurrent Opinion in Lipidology, 2021
- In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levelsNature Biotechnology, 2021
- Insulin's centenary: the birth of an ideaThe Lancet Diabetes & Endocrinology, 2020
- Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategiesCurrent Opinion in Lipidology, 2020
- Nonregulated Interventions, Clinical Trial Registration, and Editorial ResponsibilityCirculation: Cardiovascular Quality and Outcomes, 2019
- A US perspective on technology transfer: the changing role of the universityNature Reviews Molecular Cell Biology, 2004